Verici Dx Plc · LSE:VRCI
Verici Dx — FY2021 Earnings Presentation
10 slides from Verici Dx's earnings presentation, May 2022
Slide 1: Results to 31 Dec 2021
Results to 31 Dec 2021 May 2022
Slide 2: Disclaimer
DISCLAIMER THIS PRESENTATION AND ITS CONTENTS ARE NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN OR INTO OR FROM THE UNITED STATES OF AMERICA (THE "U.S.") (EXCEPT TO CERTAIN INVITED QIBS AND AIS (AS DEFINED BELOW), CANADA, AUSTRALIA, JAPAN OR ANY JURISD
Slide 3: Vision: An integrated platform yielding rich data asset for innovation
Vision: An integrated platform yielding rich data asset for innovation Data for Research Collaborations AUTO-IMMUNE DISEASES PRE-TRANSPLANT | EARLY-STAGE DAMAGE | LATE-STAGE DAMAGE Kidney Transplant Data-centric approach y y expected to increase o lo g o lo g OTHER ORGANS chn chn the pace of Te In-l
Slide 4: Indicative Robust Clinical Pathway to Revenues
Indicative Robust Clinical Pathway to Revenues Enrollment Initial endpoints All clinical completed (early data) endpoints (data to follow) Validation trials Utility completed case studies Clarava: Clinical Clarava: Clinical completed utility enrollment utility endpoints completed (data to follow) Pe
Slide 5: Points to note - Tuteva
Points to note - Tuteva High performing results – Designed to reflect the clinical reality Independent validation The test withstood the rigors of being developed and trained in one cohort while being independently validated in another cohort. International, multi-center, prospective study. Fully va
Slide 6: Upcoming commercial events
Upcoming commercial events Tuteva • Present initial data to clinical community at American Transplant Congress June 4-8, 2022 • Present to CMC pricing committee in June • Submit file to Palmetto under local coverage determination criteria • Expand commercial team and soft launch prior to end of 2022
Slide 7: Financial Results for the Year ended
Financial Results for the Year ended 31 December 2021 • Cash as at 31 December 2021 - $10.3m • March 2022 share issue raised gross proceeds of GBP10.0m • Combined funds to be used: • To maintain momentum on development of Protega • To build the expanded CLIA laboratory in Tennessee • To commercialis
Slide 8: Cash Flow Statement
Cash Flow Statement Year to 31 December 2021 Comments $’000 • Operating flows – large increase in Net outflow from operating activities (6,336) accruals for costs from trial sites reducing cash impact of EBITDA loss Investing activities (966) • Investing flows – capital spend on Financing activities
Slide 9: Income Statement
Income Statement Year to 31 December 2021 Comments $’000 • Adjusted EBITDA loss $7.1m Administrative expenses (7,151) • Largest items of expenditure: Depreciation and amortisation (438) • Wages - $1.9m Share based payments charge (741) • R&D - $2.8m Loss for the year (8,330) 9
Slide 10: Balance Sheet
Balance Sheet As of 31 December 2021 Comments $’000 • Intangible – cost of original license from Tangible assets 786 Renalytix $1.5m and additional spend on licenses and patents Intangible assets 2,008 • Receivables – mainly prepayments $406k Receivables 656 • Payables – mainly accruals $1.6m, of Ca